(Q41605739)

5 October 2017

1 reference

title

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. (English)

1 reference

metastatic renal cell carcinoma

5 October 2017

1 reference

1 reference

R M Bukowski

1

1 reference

PubMed ID

9317170

5 October 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

5 October 2017

1 reference

5 October 2017

80

1 reference

5 October 2017

1198-1220

1 reference

5 October 2017

7

1 reference

5 October 2017

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Smoking and cancer mortality among U.S. veterans: a 26-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Acquired renal cystic disease: implications for the urologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Sarcomatoid renal cell carcinoma. A treatable entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Von Hippel-Lindau disease: a genetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Inhibition of transcription elongation by the VHL tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Molecular differential pathology of renal cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The suppressor-cell network in cancer (first of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Current management of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Interferon-alpha in malignant and viral diseases. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Interferons and interleukins in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Treatment of renal cell carcinoma with escalating doses of alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Structure and expression of a cloned cDNA for human interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Cloning of the gamma chain of the human IL-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Clinical effects and toxicity of interleukin-2 in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The international standard for human interleukin-2. Calibration by international collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Nosocomial sepsis associated with interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Interleukin-2: use in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-a in the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

A Factor stimulating DNA Synthesis derived from the Medium of Leucocyte Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819971001%2980%3A7%3C1198%3A%3AAID-CNCR3%3E3.0.CO%3B2-H

10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H

21 January 2018

Identifiers

DOI

1 reference

release_elj3eam5lvezzhkbglugqvy3jm

5 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/elj3eam5lvezzhkbglugqvy3jm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

9317170

1 reference

PubMed ID

9317170